Below are the most recent publications written about "Radiation-Protective Agents" by people in Profiles.
-
Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Meyskens FL, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019 01 01; 125(1):18-44.
-
Saha S, Bhanja P, Liu L, Alfieri AA, Yu D, Kandimalla ER, Agrawal S, Guha C. TLR9 agonist protects mice from radiation-induced gastrointestinal syndrome. PLoS One. 2012; 7(1):e29357.
-
Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, Cohen GI, Emami B, Gradishar WJ, Mitchell RB, Thigpen JT, Trotti A, von Hoff D, Schuchter LM. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009 Jan 01; 27(1):127-45.
-
Tawar U, Bansal S, Shrimal S, Singh M, Tandon V. Nuclear condensation and free radical scavenging: a dual mechanism of bisbenzimidazoles to modulate radiation damage to DNA. Mol Cell Biochem. 2007 Nov; 305(1-2):221-33.
-
Bonner HS, Shaw LM. New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion. J Clin Pharmacol. 2002 Feb; 42(2):166-74.
-
Bonner HS, Shaw LM. Measurement of both protein-bound and total S-2-(3-aminopropylamino)ethanethiol (WR-1065) in blood by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 2000 Mar 10; 739(2):357-62.
-
Shaw LM, Bonner H, Lieberman R. Pharmacokinetic profile of amifostine. Semin Oncol. 1996 Aug; 23(4 Suppl 8):18-22.
-
Brown DQ, Graham WJ, MacKenzie LJ, Pittock JW, Shaw LM. Can WR-2721 be improved upon? Pharmacol Ther. 1988; 39(1-3):157-68.
-
Shaw LM, Turrisi AT, Glover DJ, Bonner HS, Norfleet AL, Weiler C, Kligerman MM. Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys. 1986 Aug; 12(8):1501-4.